Ultragenyx Pharmaceutical (RARE) CFO Horn Sells $108K of Stock

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn sold 7,066 shares of the company on October 15, 2026. The transaction was filed with the Securities and Exchange Commission via a Form 4.

RARE Ultragenyx Pharmaceutical Inc.

$14.94 ▼ -36.69% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Howard Horn's Ultragenyx Trade

Horn executed the sale at a price of $15.27 per share, netting roughly $107,897.82 in total value. Following the transaction, which was not executed under a pre-arranged Rule 10b5-1 plan, Horn directly holds 89,229 shares of the company. That represents a 7.34% reduction in his personal share count. The stock closed at $15.17 on the day of the trade.

Other Institutional Activity in Ultragenyx

Large funds continue to adjust their stakes in the biotech firm. Rtw Investments grew its holdings by 648,656 shares, ending with 3,648,795 shares worth about $88.8 million. Meanwhile, Avoro Capital Advisors completely exited its stake by selling 330,000 shares, and Baker Bros. Advisors sold out its position of 2,772,692 shares.

Ultragenyx Pharmaceutical Inc. Stock Up 1.9%

The shares recently traded around $14.81 as of October 19, 2026, down about 2.4% from their close on the day of Horn's sale. The stock trades well below its 50-day moving average of $19.03 and sits far under its 52-week high of $39.89, though it remains above its 52-week low of $12.73.

Recent Earnings

For the trailing twelve months, the company reported $717 million in revenue alongside a net loss resulting in an earnings per share of -$5.82. The net margin stands at -81.7%, while revenue grew 28.1% year-over-year. Management has scheduled the next earnings report for November 3, 2026.

Dividend

Ultragenyx does not currently pay a dividend to shareholders. The company channels its financial resources into research, development, and commercialization for rare and ultra-rare genetic treatments rather than cash distributions.

Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.

Insiders have been active throughout the second half of the year. Horn previously sold 4,696 shares on August 3, 2026, at $24.92 per share. Other recent transactions include sales by officer Karah Herdman Parschauer and officer Theodore Alan Huizenga across August and September.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks recently. On September 18, 2026, Morgan Stanley maintained its Equal-Weight rating while raising its target to $20.00. Citigroup kept a Buy rating and lifted its target to $32.00, and Canaccord Genuity maintained a Buy rating with a target raised to $39.00. Additional updates came on September 21, 2026, from Evercore ISI Group and Barclays. The stock currently holds a consensus recommendation of buy with a mean target price of $26.25.

About Ultragenyx Pharmaceutical

Headquartered in Novato, California, Ultragenyx Pharmaceutical Inc. develops and commercializes novel treatments for rare and ultra-rare genetic diseases. The company works on products targeting unmet medical needs across global markets, supported by a workforce of 1,371 employees.

Bottom Line

Investors will look to the upcoming earnings report on November 3, 2026, for fresh updates on pipeline progress and financial performance. Insider transactions like Horn's sale offer a look at executive stock management but do not necessarily signal a change in the company's operational trajectory.